{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.8","upperLimit":"88.2","value":"50.0"},{"groupId":"OG001","lowerLimit":"21.2","upperLimit":"52.8","value":"35.9"},{"groupId":"OG002","lowerLimit":"23.8","upperLimit":"53.5","value":"37.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"45"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Bortezomib + Lenalidomide + Dexamethasone, standard recommended dose according to the package insert of each drug (Treatment Period I), followed by Ixazomib (4.0 mg) on Days 1, 8 and 15, plus Lenalidomide (25 mg) on Days 1 to 21, and Dexamethasone (40 mg) on Days 1, 8, 15 and 22, of a 28-day cycle (Treatment Period II)","id":"OG000","title":"[VRd]; Bortezomib + Lenalidomide + Dexamethasone Therapy"},{"description":"Carfilzomib + Lenalidomide + Dexamethasone, standard recommended dose according to the package insert of each drug (Treatment Period I), followed by Ixazomib (4.0 mg) on Days 1, 8 and 15, plus Lenalidomide (25 mg) on Days 1 to 21, and Dexamethasone (40 mg) on Days 1, 8, 15 and 22, of a 28-day cycle (Treatment Period II)","id":"OG001","title":"[KRd]; Carfilzomib + Lenalidomide + Dexamethasone Therapy"},{"description":"Bortezomib + Lenalidomide + Dexamethasone, or Carfilzomib + Lenalidomide + Dexamethasone, standard recommended dose according to the package insert of each drug (Treatment Period I), followed by Ixazomib (4.0 mg) on Days 1, 8 and 15, plus Lenalidomide (25 mg) on Days 1 to 21, and Dexamethasone (40 mg) on Days 1, 8, 15 and 22, of a 28-day cycle (Treatment Period II)","id":"OG002","title":"[Overall]; Combination Therapy + Ixazomib Therapy"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS): all participants who were enrolled in Treatment Period I and who receive at least one dose of any therapy during the Treatment Period.","reportingStatus":"POSTED","timeFrame":"12 months","title":"Percentage of Participants Continuing Treatment With Ixazomib at 12 Months From the Start of Study Treatment","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}